The company said revenue for Q4 was $2.4 billion (up 6% on a reported basis and 4% organically), and earnings per share was $1.37 (up 2%), or $1.42 on an adjusted basis (up 20%). It attributed the increase in adjusted EPS to productivity and price.

1. 01

   The company said revenue for Q4 was $2.4 billion (up 6% on a reported basis and 4% organically), and earnings per share was $1.37 (up 2%), or $1.42 on an adjusted basis (up 20%). It attributed the increase in adjusted EPS to productivity and price.

2. 02

   Xylem reported full-year 2025 revenue of $9.0 billion, up 6% on a reported basis and 5% organically, along with earnings per share of $3.92, up 7%, and adjusted EPS of $5.08, up 19%. In the consolidated income statement for the same period, revenue was 9,035 million and operating income was 1,223 million.

3. 03

   Xylem said adjusted EBITDA margin for Q4 was 23.2%, up 220 basis points from a year earlier, and that productivity savings and strong price realization drove the margin expansion. The Board of Directors declared a dividend of $0.43 per share for Q1, an increase of 8%.

4. 04

   Xylem outlook calls for full-year 2026 revenue of about $9.1 billion to $9.2 billion, up about 2 to 4% organically, an adjusted EBITDA margin of about 22.9 to 23.3%, and a free cash flow margin of about 10.2 to 11%. Adjusted EPS is expected to be $5.35 to $5.60, the company said.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.